Medtronic (NYSE: MDT) today recognized Henning Dralle, M.D., Professor at the University of Halle-Wittenberg in Halle, Germany, who received the World Journal of Surgery award for Best Paper of 2008. Professor Dralle received the award as lead author for the paper, "Intraoperative Monitoring of the Recurrent Laryngeal Nerve in Thyroid Surgery, " published in the Feb. 2008 issue of WJS, on Sunday, Sept. 6 at the annual International Surgical Week conference in Adelaide, Australia. Professor Dralle accepted this award on behalf of the paper's co- authors and the German IONM (Intraoperative Nerve Monitoring) Study Group. "We commend Professor Dralle for his excellent work in identifying risk-minimizing tools to avoid recurrent laryngeal nerve palsy, " said Carla Pagotto, Product Manager for Intraoperative Nerve Monitoring with Medtronic ENT, part of the Surgical Technologies business at Medtronic. "Tools like Medtronic's own intraoperative nerve integrity monitors are designed to combine both hardware electronics and software to help surgeons perform critical procedures while preserving nerve function and improving patient safety.
Scientific Studies Confirm The Value Of Botulinum Toxin Type A Botox In Treating And Preventing Chronic Migraine
Four separate studies[i] representing the findings of clinical trials in the U.S., Canada and Europe have confirmed the value of onabotulinumtoxinA in treating and preventing chronic migraine in adults. These studies found that treatment with botulinum toxin type A was associated with significantly fewer headache days, less headache-related disability, and significantly improved quality of life. Results of the studies are being presented this week at the 14th International Headache Congress hosted in Philadelphia by the American Headache Society (AHS). "This is an important advance in migraine prevention, " said David Dodick, M.D., lead author of the study. "Patients afflicted with chronic migraine are severely disabled. Very few preventive treatments have been investigated for chronic migraine, and none is yet approved." Of the 36 million Americans estimated to have migraine, about 6 million suffer from chronic migraine; most are undiagnosed and inadequately treated. One of the four studies (Dodick et al.
Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient. The approval was based on several clinical trials involving more than 2, 600 patients, which confirmed the safety and efficacy of Azzalure® . This new treatment is adapted from Dysport® (botulinum toxin type-A), which is already marketed by Ipsen for therapeutic indications and has a 20-year long history of product consistency and safety.
Cleft lip and cleft palate are among the most frequent birth defects in newborns. About one in 700 infants a year in the United States and one in 600 in the United Kingdom are affected. A cleft is characterized as an opening or a split in the upper lip, the roof of the mouth (palate) or sometimes both. Cleft can have an effect on one side of the lip (unilateral cleft) or both sides of the upper lip (bilateral cleft). Most of the time, they come about as isolated birth defects, but they can also be coupled with several genetic and environmental factors which will be later explained. The look of a cleft lip can be shocking due to the disfiguration on the newborns' face. However, as surgical techniques have advanced, cleft lip and cleft palate are both correctable these days. In the majority of cases surgeons can bring back normal function with minimal scarring on the child. Cleft birth defects are more frequent in children from northern European and Asian origin, and less common in children of African ancestry.
A new technique for reconstructing the palate after surgery for tonsil cancer maintained patients' ability to speak clearly and eat most foods, a new study shows. The technique, developed at the University of Michigan Comprehensive Cancer Center, is described in the September Archives of Otolaryngology - Head & Neck Surgery. "This is the area that triggers swallowing, that separates the mouth from the nasal cavity. It affects speech and eating - typically, patients have difficulty eating when they have this kind of tumor and undergo surgery. We can remove the cancer, but there are major quality of life issues, " says study author Douglas Chepeha, M.D., M.S.P.H., associate professor of otolaryngology head and neck surgery and director of the microvascular program at the University of Michigan Health System. Tonsil cancer develops in the back of the throat, which means surgery could include parts of the palate, the tongue and the jaw. Traditional reconstruction efforts have meant taking a large, round piece of tissue to plug the hole left when the tumor is removed.
A majority of Americans oppose the inclusion of a five percent tax on cosmetic medical procedures, according to a survey released today. Survey respondents oppose the cosmetic tax by a 52% - 43% margin. According to the survey, a large majority of respondents, by a 64% - 34% margin, agree that the cosmetic medical procedures tax has no place in health care reform, since these procedures and treatments are not covered by health insurance and the tax will disproportionately impact middle class women. "It is clear from these results that Americans disagree with this proposed tax, " said Michael McGuire, MD, President of the American Society of Plastic Surgeons (ASPS). "Taxing medical procedures sets a dangerous precedent by inviting the Internal Revenue Service into the physician-patient relationship, and allowing the government to make decisions regarding medical necessity." The tax on cosmetic medical procedures was not included in any of the five health reform bills developed and debated in Senate and House Committees.
New Zilver PTX Drug-Eluting Stent From Cook Medical Could Greatly Reduce Need For Leg Amputations And Bypass Surgery For European Patients
In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union. Created by Cook Medical, a world leader in minimally invasive medical device technology for superior patient outcomes, the new CE Marked Zilver PTX Drug-Eluting Peripheral Stent is widely expected to improve the standard of care for many patients with serious blockages in the superficial femoral artery (SFA) by creating a highly effective, completely new treatment option. In the largest clinical trial of its kind ever conducted, the Zilver PTX stent was shown to effectively bridge the gap between the patient results achieved using open surgical bypass graft procedure - which is typically more painful and requires a longer hospital stay for the patient - and the less traumatic, but typically less effective, earlier minimally invasive treatment options for PAD such as balloon angioplasty and bare metal stenting1.
Whether in a quest for beauty or out of necessity, millions of Americans will have plastic surgery this year. To stay ahead of the demand, the hottest topics, technologies, and research will be presented at Plastic Surgery 2009, the annual scientific meeting of the American Society of Plastic Surgeons (ASPS), Oct. 23-27, in Seattle. The meeting, held at the Washington State Convention and Trade Center, will be attended by more than 5, 000 doctors, medical personnel and exhibitors in the field of plastic surgery. "Plastic Surgery 2009 is the complete plastic surgery experience featuring the latest information on cosmetic and reconstructive plastic surgery techniques, " said ASPS President John Canady, MD. "New discoveries on facial aging, novel uses for Botox ® to treat chronic pain, concerns about do-it-yourself cosmetic treatments and more will be explored. Amazing reconstructive surgery breakthroughs that will one day allow U.S. soldiers with artificial limbs to feel sensation will be revealed.
After 56 years of discomfort, embarrassment, and even pain, Maureen Dillon was finally able to go out in public with only one layer of makeup on. She felt beautiful for the first time since adolescence. She jumped in a pool without worrying about her makeup washing off and revealing a strawberry-colored cheek and nose. Dillon had lived with port wine stains since birth, and they became darker and brought more distress as the years went on. After dealing with blood vessel clusters and papules, swelling and infections, Dillon's family doctor sent her to see Jeffrey Orringer, M.D., director of the Cosmetic Dermatology and Laser Center at the University of Michigan Health System. Orringer used lasers that, over eight treatments, removed Dillon's port wine stains. Three of every 1, 000 children born has a port wine stain, which is made up of numerous dilated vessels in a localized part of the skin. They can occur anywhere on the body, but most laser treatment patients have port wine stains on the face or neck.
The investigational injectable filler 2.5% polyacrylamide hydrogel (AquamidR) is as effective and well tolerated as hyaluronic acid (HA, RestylaneR), for the correction of nasolabial folds, according to pivotal data released here at the 2009 American Society of Dermatologic Surgery (ASDS) meeting. In fact, the results showed the polyacrylamide hydrogel was as effective as HA at six months on the widely validated Wrinkle Assessment Scale (WAS), the study's primary endpoint. In addition, efficacy was maintained at the 12-month follow-up evaluation. "Our results demonstrate that polyacrylamide hydrogel shows strong potential as a permanent soft tissue filler, " Rhoda Narins, MD, Clinical professor of Dermatology at New York University School of Medicine in New York City and Director of the Dermatology Surgery and Laser Center of New York, said. Because polyacrylamide hydrogel is non-biodegradable and does not migrate, it is expected that efficacy will continue over a longer period than occurs with HA, she added.